BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26280620)

  • 1. Drugging the Ral GTPase.
    Yan C; Jones DN; Theodorescu D
    Small GTPases; 2015; 6(3):157-9. PubMed ID: 26280620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of small molecules that target the GTPase Ral.
    Yan C; Liu D; Li L; Wempe MF; Guin S; Khanna M; Meier J; Hoffman B; Owens C; Wysoczynski CL; Nitz MD; Knabe WE; Ahmed M; Brautigan DL; Paschal BM; Schwartz MA; Jones DN; Ross D; Meroueh SO; Theodorescu D
    Nature; 2014 Nov; 515(7527):443-7. PubMed ID: 25219851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
    Yan C; Theodorescu D
    Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.
    Guin S; Theodorescu D
    Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Ral GTPases Using a Stapled Peptide Approach.
    Thomas JC; Cooper JM; Clayton NS; Wang C; White MA; Abell C; Owen D; Mott HR
    J Biol Chem; 2016 Aug; 291(35):18310-25. PubMed ID: 27334922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules inhibit the RAS-like small GTPases RALA and RALB.
    Cancer Discov; 2014 Nov; 4(11):1251. PubMed ID: 25367937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases.
    Bum-Erdene K; Liu D; Gonzalez-Gutierrez G; Ghozayel MK; Xu D; Meroueh SO
    Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7131-7139. PubMed ID: 32179690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RalGEF/Ral pathway: evaluating an intervention opportunity for Ras cancers.
    Cooper JM; Bodemann BO; White MA
    Enzymes; 2013; 34 Pt. B():137-56. PubMed ID: 25034103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RAL signaling network: Cancer and beyond.
    Apken LH; Oeckinghaus A
    Int Rev Cell Mol Biol; 2021; 361():21-105. PubMed ID: 34074494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy: GTPase Ral-a new tumour target.
    Thoma C
    Nat Rev Urol; 2014 Dec; 11(12):658. PubMed ID: 25266572
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Discovery and Characterization of Small Molecules that Target the GTPase Ral.
    Atala A
    J Urol; 2015 Jul; 194(1):259. PubMed ID: 26088252
    [No Abstract]   [Full Text] [Related]  

  • 12. Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases.
    Hurd CA; Brear P; Revell J; Ross S; Mott HR; Owen D
    J Biol Chem; 2021; 296():100101. PubMed ID: 33214225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
    Yoshimachi S; Shirakawa R; Cao M; Trinh DA; Gao P; Sakata N; Miyazaki K; Goto K; Miura T; Ariake K; Maeda S; Masuda K; Ishida M; Ohtsuka H; Unno M; Horiuchi H
    Cancer Sci; 2021 Aug; 112(8):3064-3073. PubMed ID: 34009715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
    Feldmann G; Mishra A; Hong SM; Bisht S; Strock CJ; Ball DW; Goggins M; Maitra A; Nelkin BD
    Cancer Res; 2010 Jun; 70(11):4460-9. PubMed ID: 20484029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide activates Rap1 and Ral in a Ras-independent manner.
    Mittar D; Sehajpal PK; Lander HM
    Biochem Biophys Res Commun; 2004 Sep; 322(1):203-9. PubMed ID: 15313192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
    Pomeroy EJ; Eckfeldt CE
    Small GTPases; 2020 Jan; 11(1):39-44. PubMed ID: 28682649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ral GTPases: crucial mediators of exocytosis and tumourigenesis.
    Shirakawa R; Horiuchi H
    J Biochem; 2015 May; 157(5):285-99. PubMed ID: 25796063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential involvement of RalA and RalB in colorectal cancer.
    Martin TD; Der CJ
    Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
    Lu S; Jang H; Gu S; Zhang J; Nussinov R
    Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ral overactivation in malignant peripheral nerve sheath tumors.
    Bodempudi V; Yamoutpoor F; Pan W; Dudek AZ; Esfandyari T; Piedra M; Babovick-Vuksanovic D; Woo RA; Mautner VF; Kluwe L; Clapp DW; De Vries GH; Thomas SL; Kurtz A; Parada LF; Farassati F
    Mol Cell Biol; 2009 Jul; 29(14):3964-74. PubMed ID: 19414599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.